103286-53-9

Basic information

• Product Name: 1H-Pyrazole-4-carbonyl chloride
• Synonyms: 1H-Pyrazole-4-carbonyl chloride
• CAS NO: 103286-53-9
• Molecular Formula: C₄H₃ClN₂O
• Molecular Weight: 130.53
• Mol File: 103286-53-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrazole-4-carbonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-4-carbonyl chloride(103286-53-9)
• EPA Substance Registry System: 1H-Pyrazole-4-carbonyl chloride(103286-53-9)

Safety Data

• Hazardous Substances Data: 103286-53-9(Hazardous Substances Data)

Usage

Physical state

Colorless liquid 1H-Pyrazole-4-carbonyl chloride is a liquid without color, which is an observation of its appearance.

Reactivity

Highly reactive The compound is known for its high reactivity, which allows it to readily undergo chemical reactions.

Acylating agent

Acts as an acylating agent in organic synthesis 1H-Pyrazole-4-carbonyl chloride can donate an acyl group (carbonyl group attached to an alkyl or aryl group) to other compounds in organic synthesis.

Applications

Used in the preparation of pharmaceuticals, agrochemicals, and other organic compounds This chemical is utilized in the production of various products, including medications, chemicals for agriculture, and other organic compounds.

Safety precautions

Handle with caution and store in a cool, dry place away from moisture and strong oxidizing agents Due to its reactivity, 1H-Pyrazole-4-carbonyl chloride should be carefully managed to prevent hazardous reactions.

Main application

Synthesis of pyrazole derivatives The primary use of this compound is in the creation of pyrazole derivatives, which have a wide range of industrial and commercial applications.

Upstream product

• 37718-11-9 1H-pyrazole-4-carboxylic acid 

Downstream Products

• 1152749-21-7 morpholino(1H-pyrazol-4-yl)methanone 

Relevant articles and documents

A Hexanuclear Cadmium Metal–Organic Framework Exhibiting Dual Mechanisms to Trigger a Fluorescence-Quenching Response toward Iron(III) Ions

A hexanuclear CdII metal–organic framework (1) based on 4-(1H-pyrazole-4-carboxamido)benzoic acid (H2L) and featuring a three-dimensional microporous framework was synthesized. Notably, 1 shows a unique fluorescence-quenching response toward Fe3+ ions with high selectivity and sensitivity (Stern–Volmer constant KSV = 2.07 × 104 m–1). The response is attributable to the coaction of absorption competition and energy-transfer (ET) mechanism. Furthermore, spectral analysis indicates that the energy-transfer mechanism makes the dominant contribution to the fluorescence quenching of 1.

Preparation method of key intermediate 2 for synthesizing baricitinib

The invention relates to a preparation method of a key intermediate 2 for synthesizing baricitinib. The preparation method comprises the following process steps: respectively synthesizing an intermediate A, an intermediate B, an intermediate D and the key intermediate 2. The preparation method has the advantages that commercially available raw materials, i.e. 1H-pyrazole-4-formic acid (SM1), ethylcyanoacetate (SM2), 2-bromo-1,1-diethoxyethane (SM3) and formamidine acetate ( SM4) are used as starting materials, and the key intermediate 2 is obtained after only four steps of chemical reactionsare carried out; the use of starting materials such as 4-chloropyrrolo[2,3-d]pyrimidine and pyrazol borate which are high in material cost is avoided, and the production cost of the key intermediate 2is lowered.

Therapeutic Compounds

Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3 and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.